ESR1 and breast cancer: To further validate the risk model of CRGs constructed based on data from ER+ BC patients in TCGA-BRCA, the microarray data from 298 breast cancer patients who underwent 5 years of tamoxifen endocrine therapy and corresponding information on distant recurrent metastases were analyzed [21].